Researchers have documented the safety profile observed in published Phase 2 research as predominantly gastrointestinal effects (nausea, diarrhoea, vomiting) typical of the incretin class, occurring most prominently during dose escalation and tending to decline with continued exposure (PMID 39515565, PMID 41785010)
Massimino E, Izzo A, Riccardi G, Della PG
Standard GLP-1 dosing schedules follow fixed timelines that may not feel suitable for everyone
Oral administration must be carefully managed to avoid gastrointestinal adverse reactions
Am J Health Syst Pharm 79(23):20992117
By studying these mechanisms in controlled settings, scientists aim to understand how simultaneous engagement of complementary metabolic receptor pathways contributes to broader physiological processes